# Tuberculosis (TB) Immunotherapy Phase 2 Study

> **NCT01380119** · PHASE2 · COMPLETED · sponsor: **Lisichansk Regional Tuberculosis Dispensary** · enrollment: 40 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **BIOLOGICAL:** V7
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT01380119
- **Lead sponsor:** Lisichansk Regional Tuberculosis Dispensary
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2013-10-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01380119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01380119, "Tuberculosis (TB) Immunotherapy Phase 2 Study". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01380119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*